Key Drivers
- Liquidity Strength
- Margin Improvement
- Oversold bounce
AIAI Summary
CDNA now looks like a credible, more focused diagnostics platform with real operating leverage and strong liquidity, but the stock likely stays capped until it proves that Q1's near-breakeven profitability and margin expansion can persist through reimbursement pressure and Naveris integration risk.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Liquidity Strength
- •Margin Improvement
CDNA has a strong balance sheet and improving near-term margins, but inconsistent profitability, weak free cash flow, and a still-rich valuation keep it a mixed-risk investment.
Valuation: CDNA appears expensive relative to its sales and book value, especially given its uneven earnings and limited free cash flow.
Price Behavior
Key Price Behavior Insights:
- •Oversold bounce
- •Failed breakout
- •Support breach
CDNA fell to the low end of its last month's range after an ~11% drop, leaving it oversold but still under clear resistance until it reclaims $20.50-$21.00.
About an 11% slide from the late-April peak, with a break below $20 on 2026-05-15
Sentiment & News
Key News Insights:
- •Strong Earnings
- •Oncology Expansion
- •Product Momentum
CareDx delivered strong Q1 2026 beats, expanded into oncology with the Naveris acquisition, and boosted its growth outlook with new product launches and positive clinical momentum.
The combination of better-than-expected results, strategic expansion, and supportive product/clinical updates is likely positive for CareDx's growth narrative and investor sentiment
Similar Companies in Healthcare
Other companies in the same sector with AI ratings